Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress

  1. Mira M. Sachdevaa,
  2. Kathryn C. Claiborna,
  3. Cynthia Khooa,
  4. Juxiang Yanga,
  5. David N. Groffa,
  6. Raghavendra G. Mirmirab and
  7. Doris A. Stoffersa,1
  1. aDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism and Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, 415 Curie Boulevard, Philadelphia, PA 19104; and
  2. bDepartment of Pediatrics and the Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202
  1. Edited by Gerald I. Shulman, Howard Hughes Medical Institute/Yale University, New Haven, CT, and approved August 24, 2009 (received for review May 5, 2009)

Abstract

Type 2 diabetes mellitus (T2DM) results from pancreatic β cell failure in the setting of insulin resistance. Heterozygous mutations in the gene encoding the β cell transcription factor pancreatic duodenal homeobox 1 (Pdx1) are associated with both T2DM and maturity onset diabetes of the young (MODY4), and low levels of Pdx1 accompany β cell dysfunction in experimental models of glucotoxicity and diabetes. Here, we find that Pdx1 is required for compensatory β cell mass expansion in response to diet-induced insulin resistance through its roles in promoting β cell survival and compensatory hypertrophy. Pdx1-deficient β cells show evidence of endoplasmic reticulum (ER) stress both in the complex metabolic milieu of high-fat feeding as well as in the setting of acutely reduced Pdx1 expression in the Min6 mouse insulinoma cell line. Further, Pdx1 deficiency enhances β cell susceptibility to ER stress-associated apoptosis. The results of high throughput expression microarray and chromatin occupancy analyses reveal that Pdx1 regulates a broad array of genes involved in diverse functions of the ER, including proper disulfide bond formation, protein folding, and the unfolded protein response. These findings suggest that Pdx1 deficiency leads to a failure of β cell compensation for insulin resistance at least in part by impairing critical functions of the ER.

Footnotes

  • 1To whom correspondence should be addressed. E-mail: stoffers{at}mail.med.upenn.edu
  • Author contributions: M.M.S., K.C.C., C.K., and D.A.S. designed research; M.M.S., K.C.C., C.K., J.Y., and D.N.G. performed research; R.G.M. contributed new reagents/analytic tools; M.M.S., K.C.C., C.K., and D.A.S. analyzed data; and M.M.S. and D.A.S. wrote the paper.

  • Conflict of interest statement: D.A.S. is a coinventor on a patent entitled “Compositions and methods for detecting pancreatic disease” which covers the detection of Pdx1/Ipf1 mutations in human disease, the royalties from which were $0 during the last 12 months.

  • This article is a PNAS Direct Submission.

  • The array data have been deposited in the Array Express database, http://www.ebi.ac.uk/microarray-as/ae/ (accession no. E-MTAB-134).

  • This article contains supporting information online at www.pnas.org/cgi/content/full/0904849106/DCSupplemental.

« Previous | Next Article »Table of Contents